ESR2 and melanoma: Taken together, these data would suggest that, in melanoma patients harboring the NRAS mutation, ERβ might represent a novel molecular target for personalized therapeutic strategies, based on ERβ agonists, either alone or in combination with a specific inhibitor of the MEK pathway (i. e., trametinib).